Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Intercept Pharmaceuticals buy Quitte

Start price
€105.83
13.02.16 / 50%
Target price
€158.00
15.08.16
Performance (%)
36.86%
End price
€144.84
15.08.16
Summary
This prediction ended on 15.08.16 with a price of €144.84. With a performance of 36.86% the BUY prediction by Quitte was a big success. Quitte has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Intercept Pharmaceuticals - - - -
iShares Core DAX® 1.883% 5.122% 21.667% 22.437%
iShares Nasdaq 100 0.125% 2.574% 45.951% 55.507%
iShares Nikkei 225® -0.201% 4.341% 28.806% 9.945%
iShares S&P 500 0.728% 4.141% 34.630% 50.086%

Comments by Quitte for this prediction

In the thread Intercept Pharmaceuticals diskutieren
Prediction Buy
Perf. (%) 36.86%
Target price 158.000
Change
Ends at 15.08.16

Gerüchteküche

What: Shares ofIntercept Pharmaceuticals (NASDAQ:ICPT),a clinical stage biopharmaceutical company focused on treatingdiseases of the liver and intestines, jumped more than 27% as of 2:45p.m. EST Friday after Reuters reported that the company might belooking to sell itself.

So what: According to "sources familiarwith the matter" Intercept has been working with a group ofinvestment bankers recently to "explore the prospect of a sale."

It should be emphasized that this is still a rumor at this pointas Intercept declined to comment.

Now what: This isn't the first time that rumorshave floated around that Intercept might be a buyout target asroughly a year ago another reported surfaced saying that the companycould action itself off as it received interest from a handful oflarge pharma companies that including Gilead Sciences(NASDAQ:GILD).

If Friday's rumors do prove to be true, then Gilead Sciences mightbe an idealacquirer for Intercept as it already has a strong position theliver disease markets, so Intercept could be an interesting strategicfit. It's also worth remembering that Gilead Sciences ended 2015 with$26.2 billion in cash, so it has plenty of capital to make anacquisition if it choose to. For comparison, even with today's popIntercept's current market value is roughly $3 billion.


Prediction Buy
Perf. (%) 36.86%
Target price 158.000
Change
Ends at 15.08.16

(Laufzeit überschritten)